Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer

January 11, 2017, CU Anschutz Medical Campus
Virginia Borges, MD, MMSc is helping to shepherd tucatinib from lab to clinic. Credit: University of Colorado Cancer Center

Phase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The 50 women treated had progressed despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit from the drug, with at least "stable disease" at 24 or more weeks after the start of treatment. These data led to two subsequent Phase Ib studies, resulting in tucatinib earning FDA fast-track status and the expansion of this study once meant only to demonstrate drug safety into the "pivotal" trial that will determine approval.

"Usually we expect the results of a phase 1 clinical trial to give us data that we can use to guide the results of future treatments. This is a great case in which, for many of these patients, the results were immediate. There are women who are alive today because of this ," says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women's Breast Cancer Translational Program at the University of Colorado Cancer Center. Borges has been a major driver of the drug's development from its invention at Array Biopharm in Boulder, CO and now through of the drug, which is licensed to Cascadian Therapeutics of Seattle, WA.

Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor. The drug works by targeting the HER2 "tyrosine kinase" - a link in the chain of communication that allows HER2 receptors to signal the growth of the cell. The fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against of the disease. HER2+ is more likely to affect younger women and also more likely than other breast cancers to metastasize specifically to the brain.

Working with Borges's Young Women's Breast Cancer Translational Program at CU Cancer Center, young investigator Elena Shagisultanova, MD, PhD, recently earned a $1.4m competitive ASPIRE grant from Pfizer, Inc., to conduct a clinical trial exploring the use of tucatinib against so-called "triple positive" breast cancer - those cancers driven by both estrogen and progesterone receptors and the HER2/neu oncogene.

"When both [estrogen and HER2] are positive, they counteract the therapy aimed at one or the other, playing off each other like kids splitting parents," Borges says. More specifically, when both avenues are present, the crosstalk leads to tumors being resistant to treatment, as either avenue can allow the cancer to survive therapy. Previous trials concurrently targeting estrogen and HER2 have been, according to Borges, "lackluster," resulting in no changes to the standard of care.

The forthcoming trial lead by Shagisultanova will be a multi-center clinical trial with CU Cancer Center as the lead site, testing the combination of three drugs - tucatinib plus the anti-estrogen receptor drug letrozole and the cell cycle inhibitor palbociclib - against breast cancers positive for both HER2 and estrogen receptors.

"Tucatinib could be a substantially practice-changing drug," Borges says, meaning that in addition to the drug's current investigations as a third-, fourth-, or more-than-fifth-line treatment, she envisions its use sooner in the arc of and with far more patients.

"I think this drug has an extremely high likelihood of being approved for women with HER2+ breast cancer for use after previous treatments," Borges says. "And it's going to be an especially important drug due to its ability to control brain metastases. The opportunity to study it as a front-line drug for recurrent triple positive breast cancer could even someday help us prevent or delay these brain metastases."

Because the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.

Ongoing updates are expected in journals and meetings later in 2017.

Explore further: SABCS15: Promising phase 1 results lead to phase 2 for ONT-380 in HER2+ breast cancer

More information: Stacy Moulder-Thompson et al, Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC), Clinical Cancer Research (2017). DOI: 10.1158/1078-0432.CCR-16-1496

Related Stories

SABCS15: Promising phase 1 results lead to phase 2 for ONT-380 in HER2+ breast cancer

December 9, 2015
Results of an ongoing phase 1b clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show promise of the experimental anti-cancer agent ONT-380 against metastatic HER2+ breast cancer, especially against ...

ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'

May 29, 2015
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically ...

Discovery of potential treatment for aggressive form of breast cancer

November 2, 2016
A new drug could be used to treat one of the most aggressive forms of breast cancer, a research centre based at University College Dublin and St Vincent's Hospital has discovered.

Palbociclib efficacious in metastatic breast cancer

November 17, 2016
(HealthDay)—Palbociclib can help slow the progression of advanced breast cancer, according to a study published in the Nov. 17 issue of the New England Journal of Medicine.

Palbociclib showed antiproliferative activity in early-stage breast cancer

April 19, 2016
The molecularly targeted therapeutic palbociclib (Ibrance), which is used to treat advanced breast cancer, was effective in slowing the multiplication of cancer cells in patients diagnosed with early-stage breast cancer who ...

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.